Search

Search Results

• 

  Three-dimensional morphological condylar and mandibular changes in a patient with juvenile idiopathic arthritis: interdisciplinary treatment

  G. Farronato, C. Bellintani, U. Garagiola, P. Cressoni, P. Sarzi Puttini, F. Atzeni, M. Cazzola

  254-257

  06-11-2014

  Published: 6 November 2014

  2270

  PDF: 1251
• 

  Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment

  M. Benucci, A. Damiani, A. Arena, M. Infantino, M. Manfredi, F. Li Gobbi

  163-165

  16-12-2016

  Published: 16 December 2016

  2962

  PDF: 763
• 

  Intra-articular therapy with tumor necrosis factor-α antagonists: an update

  S. Bello, C. Bonali, L. Serafino, C. Rotondo, N. Terlizzi, G. Lapadula

  257-263

  14-03-2014

  Published: 14 March 2014

  2401

  PDF: 1175
• 

  Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs

  F.M. Perrotta, O. Addimanda, R. Ramonda, S. D’Angelo, E. Lubrano, A. Marchesoni, I. Olivieri, L. Punzi, C. Salvarani, A. Spadaro

  208-214

  06-11-2014

  Published: 6 November 2014

  2483

  PDF: 1396

• Ultrasonographic assessment of the response to Etanercept treatment in patients with rheumatoid arthritis

  A. Iagnocco, C. Perella, F. Ceccarelli, E. Tripodo, C. Alessandri, L. Magrini, G. Valesini

  233-238

  Published:

  981

  PDF: 955

• Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis

  S. Bellissimo, M.G. Ferrucci, A. Gallo, S. Stisi

  240-243

  Published:

  976

  PDF: 1098

• Anti-TNFa treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies

  I. Cavazzana, F. Franceschini, E. Danieli, M. Frassi, M. Vianelli, R. Gorla, P. Airò, R. Cattaneo

  267-272

  Published:

  996

  PDF: 1548

• Intra-articular etanercept treatment for severe diffuse pigmented villonodular knee synovitis

  U. Fiocco, P. Sfriso, F. Oliviero, F. Sovran, E. Scagliori, E. Pagnin, M. Vezzù, L. Cozzi, C. Botsios, R. Nardacchione, A. Di Maggio, L. Rubaltelli, C. Giacometti, F. Calabrese, S. Todesco

  268-274

  Published:

  1478

  PDF: 2627

• The treatment of recurrent uveitis with TNFα inhibitors

  P.C.F. Falappone, F. Iannone, C. Scioscia, V. Grattagliano, M. Covelli, G. Lapadula

  185-189

  Published:

  1688

  PDF: 2294
• 

  Psoriatic arthritis: treatment strategies using biologic agents

  S. D'Angelo, C. Palazzi, I. Olivieri

  113-121

  05-06-2012

  Published: 5 June 2012

  1108

  PDF: 1133

• Biologic therapy with anti-TNFa in spondyloarthritides and other autoimmune diseases

  G. Lapadula

  22-29

  Published:

  722

  PDF: 1040

• Side effects of anti-TNFa therapy in juvenile idiopathic arthritis

  Irene Pontikaki, Valeria Gerloni, Maurizio Gattinara, Alfredomaria Lurati, Alessandra Salmaso, Gabriele De Marco, Barbara Teruzzi, Elisabetta Valcamonica, Flavio Fantini

  31-38

  Published:

  1744

  PDF: 2483

• Safety of anti-TNFa biological drugs

  F. Trotta, G. Valentini

  34-39

  Published:

  1075

  PDF: 1070
• 

  Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

  C. Gioia, A. Picchianti Diamanti, R. Perricone, M.S. Chimenti, A. Afeltra, L. Navarini, A. Migliore, U. Massafra, V. Bruzzese, P. Scolieri, C. Meschini, M. Paroli, R. Caccavale, P. Scapato, R. Scrivo, F. Conti, B. Laganà, M. Di Franco

  19-12-2023

  Published: 19 December 2023

  1550

  PDF: 348
• 

  Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case

  V. Shobha, A.M. Desai, T. Matthew

  99-102

  09-07-2019

  Published: 9 July 2019

  1127

  PDF: 705
• 

  A short history of anti-rheumatic therapy - VII. Biological agents

  G. Pasero, P. Marson, B. Gatto

  185-194

  09-11-2011

  Published: 9 November 2011

  1286

  PDF: 1190
• 

  Jaccoud’s arthropathy, an unusual manifestation of idiopathic retroperitoneal fibrosis: rapid improvement of symptoms after tocilizumab treatment

  M. Benucci, A. Damiani, F. Li Gobbi, V. Grossi, M. Infantino, A. Arena, M. Manfredi

  88-91

  03-08-2017

  Published: 3 August 2017

  1845

  PDF: 915
• 

  GISEA: an Italian biological agents registry in rheumatology

  G. Lapadula, G. Ferraccioli, C. Ferri, L. Punzi, F. Trotta

  155-164

  09-11-2011

  Published: 9 November 2011

  1908

  PDF: 1466

• A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens

  Giovanna Cuomo, Gabriella Molinaro, Giovanni La Montagna, Sergio Migliaresi, Gabriele Valentini

  22-25

  Published:

  1455

  PDF: 1939

• Inflammatory back pain as an unusual manifestation of Takayasu arteritis: a case report

  F.I. Gorial, N.I. Awadh, A. Al-Shakarchi, G. Al-Gburi

  30-10-2024

  Published: 30 October 2024

  288

  PDF: 124

• Recurrent new-onset uveitis in a patient with rheumatoid arthritis during anti-TNFα treatment

  M. Di Gangi, R. Foti, R. Leonardi, C. Leonetti, P. Castellino

  169-172

  Published:

  918

  PDF: 845

• Correlation between radiographic, echographic and MRI changes and rheumatoid arthritis progression

  M.A. Cimmino, M. Parodi, E. Silvestri, G. Garlaschi

  28-40

  Published:

  926

  PDF: 2904

• Approved indications and other possible utilizations of anti-TNFa biologic drugs

  W. Grassi, C. Montecucco

  30-33

  Published:

  1078

  PDF: 843

• Analysis of the kinetic of expression of tristetraprolin and HuR by rheumatoid arthritis patients pheripheral blood mononuclear cells stimulated with lipopolysaccharide

  M. Fabris, B. Tolusso, E. Gremese, P. Tomietto, G. Ferraccioli

  94-103

  Published:

  1270

  PDF: 894

• Biologic therapy with anti-TNFa in rheumathoid atrhritis

  G. Ferraccioli

  17-21

  Published:

  722

  PDF: 630

• Are there any positive effects of TNF-alpha blockers on bone metabolism?

  B. Seriolo, S. Paolino, A. Sulli, M. Cutolo

  199-205

  Published:

  1148

  PDF: 1075

• Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects

  C. Botsios, P. Ostuni, P. Sfriso, A. Furlan, U. Fiocco, D. Sgarabotto, S. Todesco

  224-235

  Published:

  1050

  PDF: 2296

• Differences in pharmacology of tumor necrosis factor (TNF) antagonists

  U. Fiocco, S. Bombardieri

  8-16

  Published:

  1083

  PDF: 1724

• Kidney involvement in rheumatoid arthritis

  A. Icardi, P. Araghi, M. Ciabattoni, U. Romano, P. Lazzarini, G. Bianchi

  76-85

  Published:

  5285

  PDF: 7481

• Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature

  R. Scrivo, F. Conti, F.R. Spinelli, S. Truglia, L. Magrini, M. Di Franco, F. Ceccarelli, G. Valesini

  107-117

  Published:

  1818

  PDF: 1068

• Effects of TNF antagonists on immune and neuroendocrine system

  G. Valesini, M. Cutolo

  3-7

  Published:

  1097

  PDF: 710